Wegovy (Semaglutide)

If Ozempic is the name everyone knows, Wegovy is the one that made the weight loss numbers impossible to ignore.

Wegovy is semaglutide — the same active ingredient as Ozempic — but it was developed, tested, and FDA-approved specifically for chronic weight management. It goes to a higher dose than Ozempic, and the clinical trials were designed to measure weight loss as the primary goal, not a secondary observation.

This page covers everything about Wegovy: how the injection works, the research behind it, the cardiovascular trial that redefined what this medication class can do, the brand-new pill form, what it costs, and who it’s designed for.

---

The Basics

Wegovy is made by Novo Nordisk. The active ingredient is semaglutide — the same molecule in Ozempic and Rybelsus.

FDA-approved indications (as of early 2026):

1. Chronic weight management — for adults with a BMI of 30 or higher, or BMI of 27+ with at least one weight-related health condition. Used alongside reduced calorie intake and increased physical activity. (June 2021)
2. Chronic weight management in adolescents — for patients aged 12 and older with a BMI at or above the 95th percentile for their age and sex. (December 2022)
3. Cardiovascular risk reduction — to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease who are overweight or obese. (March 2024)
4. MASH (metabolic dysfunction-associated steatohepatitis) — for treatment of non-cirrhotic MASH with moderate to advanced liver scarring. This is what used to be called NASH, or severe fatty liver disease with inflammation. (August 2025, accelerated approval)
5. Oral formulation — a once-daily pill for weight management and cardiovascular risk reduction. (December 2025)

That’s five distinct FDA approvals. No other GLP-1 medication has this many.[1]

---

The Injectable: How It Works

The Pen

Unlike Ozempic’s multi-dose pen (where you dial your dose), Wegovy uses single-dose, pre-filled pens. Each pen delivers one fixed dose and gets discarded after use. The needle is pre-attached — no setup, no fiddling with removable needle tips.

You use one pen per week, which means four pens per monthly supply. That’s more pens to store than Ozempic’s one-per-month approach, but the trade-off is simplicity: there’s nothing to dial, nothing to attach, and zero chance of accidentally selecting the wrong dose.[2]

Dosing Schedule (Injectable)

Wegovy’s dose escalation takes 16 weeks before reaching the maintenance dose — one step longer than Ozempic, because the target dose is higher.

If a dose increase is hard to tolerate, your provider can extend any step by an additional four weeks before moving up. Some people settle at 1.7 mg as their maintenance dose if 2.4 mg causes too many side effects — and that’s a valid approach, not a compromise.[3]

---

The Pill: Wegovy Goes Oral

In December 2025, the FDA approved a once-daily Wegovy pill — the first oral GLP-1 medication approved specifically for weight management. This is a major development for people who want GLP-1 benefits without weekly injections.[4]

How the Pill Is Dosed

Those daily milligram numbers look much higher than the injection doses, and there’s an important reason for that. When you swallow semaglutide, your stomach acid and digestive enzymes destroy most of it before it can absorb. Even with the improved absorption technology in the pill, only about 1-2% of the semaglutide you swallow actually reaches your bloodstream. The rest is broken down. So the 25 mg daily pill delivers roughly comparable blood levels to the 2.4 mg weekly injection — just by a very different route.[5]

The Morning Routine (Non-Negotiable)

Taking the Wegovy pill isn’t like taking a regular medication. The absorption process requires specific conditions, and skipping these steps can mean the medication barely works:

• Take it first thing in the morning, on an empty stomach
• Swallow it whole with plain water only — no more than 4 ounces (about half a glass)
• Wait at least 30 minutes before eating, drinking anything else, or taking other medications
• Don’t crush, chew, or split the tablet

This isn’t lifestyle advice — it’s a pharmacological requirement. Studies showed that people who ate before taking the tablet had almost no detectable semaglutide in their blood. The fasting window is the price of admission for making an oral peptide drug work.

How the Pill Compares to the Injection

The clinical trial for the pill (called OASIS 4) showed 16.6% mean body weight loss at 64 weeks — comparable to the 14.9% seen with the injectable in STEP 1. One in three patients on the pill lost 20% or more of their body weight.[6]

The trade-off is straightforward: no needles, but you need to follow the daily fasting routine. The injection is once a week — take it and forget about it for seven days. The pill is every single morning with a mandatory routine. Some people strongly prefer one over the other. Neither is objectively better — it depends on what matters most to you.

---

What the Research Shows

Wegovy’s evidence base is one of the strongest for any weight management medication in history. Here are the trials that matter most.

STEP 1: The Headline Trial

This is the trial that changed the conversation about GLP-1 medications and obesity.

• Who: 1,961 adults with obesity (or overweight with a weight-related health condition), WITHOUT diabetes
• What: Wegovy 2.4 mg weekly vs. placebo, both with lifestyle changes
• How long: 68 weeks (about 16 months)

The results:[7]

Read that last row again: one in three people on Wegovy lost at least 20% of their body weight. For someone starting at 250 lbs, that’s 50 lbs. These numbers were unlike anything seen before with a weight management medication.

STEP 3: With Intensive Behavioral Support

This trial added intensive behavioral therapy (30 counseling sessions over the treatment period) and a low-calorie diet for the first eight weeks.

The result: 16% mean weight loss — the highest in the STEP program. Three out of four patients lost at least 10% of their body weight. The takeaway: the medication works best when combined with real behavioral and dietary support. It’s not either/or.[8]

STEP 5: Does It Last?

This trial ran for two full years — the longest in the program.

At 104 weeks, patients on Wegovy maintained an average weight loss of 15.2%. That’s nearly identical to the 68-week results from STEP 1, confirming something important: the weight loss plateaus and holds rather than bouncing back, as long as you keep taking the medication.[9]

---

The SELECT Trial: Heart Protection

This is the trial that fundamentally reframed what GLP-1 medications can do beyond weight loss.

The setup: 17,604 adults aged 45 and older with established heart disease (prior heart attack, stroke, or peripheral artery disease) and a BMI of 27 or higher — but WITHOUT diabetes. They were randomized to Wegovy 2.4 mg or placebo and followed for an average of 40 months.

The headline result: Wegovy reduced the risk of major cardiovascular events — heart attack, stroke, or death from heart disease — by 20%.[10]

In practical terms: for every 1,000 people with heart disease and excess weight treated with Wegovy for about three years, approximately 15 fewer would experience a heart attack, stroke, or cardiovascular death compared to those not taking it. That’s a meaningful reduction — comparable to established heart medications like statins.

Was it just about the weight loss? No — and this is the important part. Analysis of the trial data found that only about one-third of the heart benefit was explained by weight loss. The remaining two-thirds appeared to come from other mechanisms — likely anti-inflammatory effects, reduced plaque inflammation in arteries, and direct vascular benefits of GLP-1 receptor activation. This led researchers to describe semaglutide as a disease-modifying cardiovascular treatment, not merely a weight loss drug with secondary heart benefits.[11]

In March 2024, the FDA approved Wegovy for a new indication based on SELECT: reducing the risk of cardiovascular death, heart attack, and stroke in adults with heart disease who are overweight or obese. It was the first anti-obesity medication ever approved for heart protection.

---

MASH: Liver Disease Approval

In August 2025, the FDA granted Wegovy accelerated approval for treating MASH — metabolic dysfunction-associated steatohepatitis. If that sounds like a lot of words, here’s the plain version: it’s a form of fatty liver disease where the fat buildup has caused inflammation and scarring in the liver.

The approval covers patients with moderate to advanced liver scarring (fibrosis stages F2 and F3 — significant scarring but not yet cirrhosis). The supporting trial (ESSENCE) showed that 63% of patients on Wegovy had their liver inflammation resolve, compared to 34% on placebo.[12]

This is an accelerated approval, which means the full confirmation depends on longer-term data (expected around 2029) showing that it actually prevents liver failure and transplants — not just improves the markers. But the early results were strong enough for the FDA to act.

---

For Adolescents (Age 12+)

Wegovy was the first once-weekly anti-obesity medication approved for adolescents. The approval (December 2022) was based on the STEP TEENS trial, which showed that adolescents aged 12-17 lowered their BMI by 16.1% — actually a numerically larger effect than what was seen in adults.[13]

The same dose escalation applies (up to 2.4 mg weekly), and it’s approved for adolescents with a BMI at or above the 95th percentile for their age and sex.

---

Cost and Access

Wegovy’s cost picture is complicated — partly because it’s a weight management drug (which many plans treat differently than diabetes drugs), and partly because it’s changing rapidly.

What Wegovy Costs

Insurance Coverage

Here’s the honest picture: Wegovy coverage is improving but still inconsistent.

• Commercial insurance: Most major plans now have some pathway to cover Wegovy, but almost all require prior authorization — meaning your provider’s office has to submit documentation that you meet the criteria before insurance will approve it. Typical requirements include BMI documentation, evidence of previous weight loss attempts (usually 3-6 months), and sometimes a failed trial on a cheaper medication first.
• Medicare: Historically, Medicare didn’t cover anti-obesity medications at all. That’s changing. Wegovy’s cardiovascular indication opened a pathway for Medicare Part D coverage when prescribed specifically for heart risk reduction (not weight loss alone). As of early 2026, the government has announced deals to provide Medicare coverage at reduced prices (~$245/month), with full implementation expected in 2027.[14]
• Manufacturer savings: Novo Nordisk reports that 90% of commercially insured patients pay $0–$25/month with their savings programs.

---

Storage

Since Wegovy pens are single-dose (one per week), most people keep unused pens in the fridge and only take out the one they plan to use. The 28-day room-temperature window is mainly relevant for travel.[15]

---

The Bottom Line

Wegovy is the GLP-1 medication designed from the ground up for weight management — and the clinical evidence behind it is remarkable. Average weight loss of nearly 15%. Heart attack and stroke risk reduced by 20%. Liver disease improvement. An adolescent indication. And now a pill option for people who don’t want injections.

It’s also expensive, insurance coverage is inconsistent, and the daily pill requires a strict morning routine. None of that should be sugarcoated. But in terms of what the medication can do when you can access it, Wegovy represents a genuine shift in how medicine approaches obesity — not as a lifestyle failure, but as a chronic condition with effective treatment.

If you’re considering Wegovy, you’re considering one of the most studied and most effective weight management tools available. Take that information to your provider and have the conversation.

---